Journal of Alzheimer's Disease · Nov 18, 2026
Circular RNAs as emerging multi-pathway blood-based biomarkers for Alzheimer's disease: Clinical need, biological rationale, and translational considerations
By DeHart J, Song SS, Janve VA et al.
Alzheimer's disease (AD) remains underdiagnosed in its earliest and most modifiable stages. Most patients present in primary care with mild cognitive concerns, yet diagnostic pathways are fragmented, specialist-dependent, and poorly optimized for scalable early detection, while specialists face rising referral volume and limited capacity. Positron emission tomography, cerebrospinal fluid biomarkers, and blood-based biomarkers (BBMs) are constrained by accessibility, reimbursement, indeterminate results, and inconsistent performance across populations and disease stages. This narrative review summarizes clinical and system-level barriers across primary and specialty care and highlights emerging biomarker strategies supporting earlier diagnosis. Within the expanded A/T/N/X framework, biomarkers capturing upstream, multi-domain signals may enable earlier, more comprehensive detection. Circular RNAs (circRNAs), a novel class of BBMs, are highly stable, brain-enriched, and detectable in peripheral blood, enabling minimally invasive testing. Specific circRNAs have been shown to be altered in AD and associated with core AD mechanistic processes, including circHOMER1 in synaptic function, circAβ-a and circPSEN1 in amyloid processing, circTau6 in tau pathology, and circTREM2 in neuroinflammation. In the largest blood-based circRNA study to date, a 34-circRNA signature classified biomarker-confirmed AD with an area under the curve of 0.945 versus 0.877 for plasma p-tau217, predicted progression to symptomatic AD more strongly than p-tau217 (hazard ratio 2.92 versus 1.81), showed low predictive power in non-AD dementias, and changed 2–4 years before symptom onset. These features position circRNAs as candidates for next-generation blood-based diagnosis that could streamline triage and reduce reliance on confirmatory testing. Prospective validation, assay standardization, and health economic evidence remain essential.